Evexia Lifecare Revenue Surge Mixed With Auditor's Financial Risk Warnings

Evexia Lifecare Ltd reported consolidated revenue of ₹36.89 crore and net profit of ₹0.78 crore in Q4 FY26. Standalone revenue for the quarter reached ₹35.73 crore, with a profit of ₹0.47 crore.

What Happened

Evexia Lifecare Ltd announced its financial results for the quarter and year ended March 31, 2026, showing strong revenue growth.

On a standalone basis, the company posted total revenue of ₹35.73 crore for Q4 FY26, a significant 134.83% increase year-on-year from ₹15.21 crore in the prior year.

Consolidated revenue for Q4 FY26 also grew substantially, up 56.21% year-on-year to ₹36.89 crore from ₹23.61 crore. The company maintained profitability across all reported periods.

For the full financial year FY26, standalone revenue grew 26.57% to ₹106.35 crore. Consolidated revenue rose 27.15% to ₹110.28 crore, with a net profit of ₹1.62 crore for the year.

Why It Matters

Despite the strong revenue performance, the company's financial statements face scrutiny due to a qualified opinion from its statutory auditors. This signals that auditors could not obtain sufficient evidence for certain financial details or encountered significant disagreements.

Specific auditor concerns include unassessed credit risk on loans and trade receivables, totaling over ₹36 crore, and doubts about the viability of a subsidiary, 'Kavit Edible Oil Limited'. These issues raise questions about the accuracy and reliability of the reported financials.

Company Background

Evexia Lifecare Ltd operates in the pharmaceutical sector, manufacturing and trading pharmaceutical formulations and active pharmaceutical ingredients (APIs). Historically, the company has undertaken fundraising and other corporate activities to support its operations and expansion.

What Changes Now

Shareholders can expect increased scrutiny of the company's financial health and internal controls. The qualified audit report requires the company's board to investigate the auditor's findings more closely, potentially involving regulatory bodies.

The doubts about the going concern status of 'Kavit Edible Oil Limited' could lead to write-downs or restructuring if unresolved, further impacting consolidated financials. Investors may need to re-evaluate their risk tolerance given the potential for misstated figures and unverified balances.

Risks to Watch

The primary risk is the qualified auditor opinion itself, indicating potential inaccuracies in financial reporting. Significant unassessed credit risk on loans (₹7.35 crore) and trade receivables (₹29.44 crore) could result in future write-offs, directly affecting profitability.

The subsidiary 'Kavit Edible Oil Limited', suspended since 2019 with a negative net worth and an exposure of ₹1.28 crore, presents a substantial going concern risk for the consolidated entity. Instances of material misstatements, improper valuation, and missing documentation flagged by auditors point to weaknesses in internal financial controls and record-keeping.

Peer Comparison

Competitors like Aarti Drugs and Indoco Remedies, operating in the pharmaceutical API and formulation sector, reported FY24 revenues between ₹1,700-₹2,400 crore and net profits exceeding ₹130 crore. These peers show stronger financial performance and likely more robust reporting structures. Evexia Lifecare's high revenue growth is notably distinct from these peers due to its financial integrity concerns.

What to Track Next

Investors should closely monitor the company's response to the auditor's qualified opinion and the steps it plans to take to address the identified issues. Clarity on the resolution or implications of the going concern doubt for 'Kavit Edible Oil Limited' will be crucial. Further regulatory announcements or clarifications from the company regarding financial reporting discrepancies are also important. Subsequent quarterly results will show if the company can sustain its revenue growth while improving financial transparency and internal controls.